Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Beigene Ltd ADR
(NQ:
BGNE
)
194.66
+3.77 (+1.97%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Beigene Ltd ADR
< Previous
1
2
3
4
5
6
7
Next >
BeiGene to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
June 08, 2022
From
BeiGene
Via
Business Wire
BeiGene Clinical Data Presentations at 2022 ASCO Annual Meeting Demonstrate Mature and Growing Oncology Portfolio
May 26, 2022
From
BeiGene
Via
Business Wire
BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Switzerland
May 17, 2022
From
BeiGene, Ltd.
Via
Business Wire
BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hematology Association 2022 Congress
May 12, 2022
From
BeiGene
Via
Business Wire
BeiGene Reports First Quarter 2022 Financial Results
May 05, 2022
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)
May 04, 2022
From
BeiGene
Via
Business Wire
BeiGene Breaks Ground on New Manufacturing and Clinical R&D Center at the Princeton West Innovation Campus in New Jersey
April 29, 2022
From
BeiGene
Via
Business Wire
BeiGene Announces BRUKINSA (zanubrutinib) Approval in Uruguay in Mantle Cell Lymphoma, Marginal Zone Lymphoma, and Waldenström’s Macroglobulinemia
April 28, 2022
From
BeiGene
Via
Business Wire
BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual Meeting
April 27, 2022
From
BeiGene
Via
Business Wire
Global Phase 3 Trial of BeiGene’s PD-1 Inhibitor, Tislelizumab, in Combination with Chemotherapy Meets Primary Endpoint in First-Line Advanced Esophageal Squamous Cell Carcinoma
April 27, 2022
From
BeiGene
Via
Business Wire
BeiGene Introduces Global Environmental, Social, and Governance Strategy
April 26, 2022
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Provides Grant to Crossroads4Hope to Fund Psychosocial Support Programs for Cancer Patients and Communities in New Jersey
April 21, 2022
From
BeiGene
Via
Business Wire
BeiGene Presents Updated Results from Phase 3 RATIONALE-309 Trial of PD-1 Inhibitor Tislelizumab in First-Line RM-NPC in Virtual ASCO Plenary Series
April 19, 2022
From
BeiGene
Via
Business Wire
China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell Carcinoma
April 15, 2022
From
BeiGene
Via
Business Wire
IRC Determines BRUKINSA® (Zanubrutinib) Demonstrates Superior Overall Response Rate Versus Ibrutinib in Final Response Analysis of ALPINE Trial in Chronic Lymphocytic Leukemia
April 11, 2022
From
BeiGene, Ltd.
Via
Business Wire
BeiGene to Present Clinical Results and Biomarker Data on Tislelizumab in Solid Tumors at the AACR Annual Meeting 2022
April 08, 2022
From
BeiGene
Via
Business Wire
BeiGene Announces European Medicines Agency Acceptance of Marketing Authorization Applications for Tislelizumab for the Treatment of Patients with ESCC and NSCLC
April 06, 2022
From
BeiGene
Via
Business Wire
BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA® (zanubrutinib) for the Treatment of Waldenström's Macroglobulinemia
March 15, 2022
From
BeiGene
Via
Business Wire
BeiGene Reports Fourth Quarter and Full Year 2021 Financial Results
February 25, 2022
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia
February 22, 2022
From
BeiGene
Via
Business Wire
BeiGene Announces European Medicines Agency Acceptance of Applications for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia and Marginal Zone Lymphoma
February 22, 2022
From
BeiGene
Via
Business Wire
BeiGene Announces Approval for BRUKINSA (zanubrutinib) by Swissmedic for Treatment of Adult Patients with Waldenström’s Macroglobulinemia
February 17, 2022
From
BeiGene
Via
Business Wire
BeiGene to Present at the Guggenheim Healthcare Talks - 2022 Oncology Conference
February 08, 2022
From
BeiGene, Ltd.
Via
Business Wire
Drs. Margaret Dugan and Alessandro Riva Appointed to BeiGene Board of Directors
February 01, 2022
From
BeiGene
Via
Business Wire
BeiGene Announces Acceptance of Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia with Breakthrough Therapy Designation
January 28, 2022
From
BeiGene
Via
Business Wire
Billions Flowing into Cancer Immunotherapy as Market Responds to Impressive Market Potential
January 24, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 24, 2022 – USA News Group – Within the grand battle against cancer, the use of immunotherapy continues to grow at...
Via
FinancialNewsMedia
BeiGene Announces Positive Findings from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy in First-Line Gastric or Gastroesophageal Junction Cancer
January 24, 2022
From
BeiGene
Via
Business Wire
BeiGene Announces Acceptance of a Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Waldenström’s Macroglobulinemia
January 20, 2022
From
BeiGene
Via
Business Wire
BeiGene to Present at the J.P. Morgan 40th Annual Healthcare Conference
January 06, 2022
From
BeiGene, Ltd.
Via
Business Wire
China NMPA Approves Tislelizumab as Second- or Third-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer
January 06, 2022
From
BeiGene
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.